Imatinib-mesylate for all patients with hypereosinophilic syndrome? [PDF]
, 2004 Some recent papers have focused on the activity of imatinib-mesylate, a selective inhibitor of tyrosine kinase, in idiopathic hypereosinophilic syndrome (HES) [1], [2], [3] and [4].
Carella, A +5 more
core +1 more source
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis [PDF]
, 2017 Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use. Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF ...
Distler, J. H. W., Distler, O.
core
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
Acta Medica, 2003 The publication provides an up-to-date review of the significance of cytogenetic abnormalities in chronic myelogenous leukemia (CML) and the development of a promising agent with specific molecular target against tyrosine kinase, product of the BCR-ABL ...
Ladislav Chrobák, Jaroslava Voglová
doaj +1 more source
Studying the impact of presence of alpha acid glycoprotein and protein glycoprotein in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar [PDF]
, 2015 Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML), there is a high degree of resistance. Alpha- 1-acid glycoprotein may reduce drug efficacy through its ability to interact with IM and blocks it from reaching its ...
Branford S. +4 more
core +2 more sources
Indian Journal of Medical and Paediatric Oncology, 2013 Post Graduate Institute (PGI) Chandigarh is a premier institute of North India. There are approximately 70,000 admissions per year. The adult clinical hematology department sees more than 2000 new patients per year.
Pankaj Malhotra +2 more
doaj +1 more source
Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model [PDF]
, 2009 Background: We have previously shown that small molecule PDGF receptor tyrosine kinase inhibitors (RTKI) can drastically attenuate radiation-induced pulmonary fibrosis if the drug administration starts at the time of radiation during acute inflammation ...
Minglun Li +5 more
core +2 more sources
Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia
Haematologica, 2010 As chronic myeloid leukemia is rare in children, most data on imatinib mesylate therapy is derived from adult studies. We retrospectively evaluated pediatric (
Asim F. Belgaumi +6 more
doaj +1 more source
Haematologica, 2008 Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival.
Francesca Palandri +21 more
doaj +1 more source
Sequence analysis and high-throughput immunhistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays [PDF]
, 2018 We aimed to immunohistochemically examine the expression of KIT (CD 117) in human posterior uveal melanoma and to analyze KIT-positive tumors for gene mutations.
Bösch, Doris +10 more
core
Periorbital edema secondary to imatinib mesylate
Clinical Ophthalmology, 2010 Collin M McClelland, George J Harocopos, Philip L CusterSchool of Medicine, Washington University, St. Louis, MO, USAAbstract: Imatinib mesylate (Gleevec®) is a well-established pharmacologic treatment for all phases of chronic myeloid leukemia ...
Collin M McClelland +2 more
doaj